Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma

ASCO23 Plenary Session looking at Nivo-AVD vs. BV-AVD is going to change the landscape for Hodgkin’s Lymphoma. Here are results for a phase II on Pembro-AVD (APVD). We need to move past interim PET and move towards ct-DNA!

TFOC Takeaways:
– Incredible PFS at 2 years: 97%
– Interim PET2 negative: only 57%
– EOT PET negative: only 87%
– None of the patients with ct-DNA cleared had relapse regardless of PET results

Read the full article here

Related Articles